Long-term montelukast therapy in moderate to severe COPD - A preliminary observation

Respiratory Medicine

Volumn 98, Issue 2, 2004, Pages 134-138

  Rubinstein, Israel ^a,b   Kumar, Brijesh ^a,b   Schriever, Christopher ^c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Acute exacerbation; Airway; Bronchodilators; Corticosteroids; Cysteinyl leukotrienes; Inflammation

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; MONTELUKAST; OXYGEN; PEPTIDOLEUKOTRIENE; PREDNISONE;

ADULT; AFRICAN AMERICAN; AGED; AMBULATORY CARE; BREATHING DISORDER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EMERGENCY WARD; FORCED EXPIRATORY VOLUME; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; INFORMATION PROCESSING; LENGTH OF STAY; LONG TERM CARE; MALE; MEDICAL RECORD; OXYGEN THERAPY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SPUTUM; TREATMENT OUTCOME; UNITED STATES; WHEEZING;

EID: 0842323816     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2003.09.003     Document Type: Article

References (23)

1. National Heart, Lung and Blood Institute, World Health Organization. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO, Workshop Report, Publication No. 2701, National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda, MD, 2001.
2. National Heart, Lung, and Blood Institute. Mortality and morbidity: 2000 chart book on cardiovascular, lung and blood diseases. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD, 2000.
3. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of diseases study. Lancet 1997;349:1498-504.
4. Barnes PJ. New treatments for COPD. Nat Rev Drug Discov 2002;1:437-46.
5. McMillan RM. Leukotrienes in respiratory disease. Paediatr Respir Rev 2001;2:238-44.
6. Leff A. The Antileukotriene Working Group. Discovery of leukotrienes and development of antileukotriene agents. Ann Allergy Asthma Immunol 2001;86(Suppl 1):4-8.
7. O'Driscoll BR, Cromwell O, Kay AB. Sputum leukotrienes in obstructive airways diseases. Clin Exp Immunol 1984;55: 397-404.
8. Zakrzewski JT, Barnes NC, Piper PJ, Costello JF. The detection of 5-lipoxygenase and cyclooxygenase products in sputum of patients with chronic bronchitis and bronchiectasis. Prostaglandins 1987;33:663-74.
9. Zakrzewski JT, Barnes NC, Costello JF, Piper PJ. Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am Rev Respir Dis 1987;136:779-82.
10. Damon M, Chavis C, Crastes de Paulet A, Michel FB, Godard P. Arachidonic acid metabolism in alveolar macrophages. A comparison of cells from healthy subjects, allergic asthmatics, and chronic bronchitis patients. Prostaglandins 1987;34:291-309.
11. Mitsunobu F, Mifune T, Hosaki Y, et al. Enhanced production of leukotrienes by peripheral leukocytes; and specific IgE antibodies in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2001;107:492-8.
12. 4 in chronic obstructive pulmonary disease. Chest 1993;104:454-9.
13. 4 during clinical course of chronic obstructive pulmonary disease. Prostaglandins Leukot Essent Fatty Acids 1997;56:213-7.
14. 1-receptor antagonist. Pulm Pharmacol Ther 2000;13:301-5.
15. Cazzola M, Centanni S, Boveri B, et al. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatment in asthma and chronic obstructive pulmonary disease. Respiration 2001;68:452-9.
16. Gompertz S, Stockley RA. A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 2002;122:289-94.
17. Iqbal A, Schloss S, George D, Isonaka S. Worldwide guidelines for chronic obstructive pulmonary disease: a comparison of diagnosis and treatment recommendations. Respirology 2002;7:233-9.
18. Noonan GP, Williams B, Angner R, Lu S, Knorr B, Reiss TF. Use of oral montelukast in the treatment of asthma. Compr Ther 2001;27:148-55.
19. Kilfeather S. 5-Lipoxygenase inhibitors for the treatment of COPD. Chest 2002;121(5 Suppl):197S-200S.
20. Morice AH, Kastelic JA, Aziz I. Montelukast sodium in cystic fibrosis [letter]. Thorax 2001;56:244-5.
21. American Thoracic Society. Standards for the diagnosis, care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-121.
22. 4 receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors. Am J Respir Crit Care Med 1999;160:2079-85.
23. Peters-Golden M, Brock TG. 5-Lipoxygenase and FLAP. Prostaglandins Leukot Essent Fatty Acids 2003;69:99-109.